GALDERMA GROUP AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.38 CHF | +0.06% |
|
+1.83% | 0.00% |
| May. 23 | Galderma Group AG Launches Restylane VOLYME in China | CI |
| May. 15 | Ten key beauty players |  |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 19,468 | - | - |
| Enterprise Value (EV) 1 | 21,820 | 21,275 | 20,573 |
| P/E ratio | 99.3 x | 39.5 x | 25.5 x |
| Yield | 0.04% | 0.34% | 0.59% |
| Capitalization / Revenue | 4.4 x | 3.92 x | 3.43 x |
| EV / Revenue | 4.93 x | 4.28 x | 3.63 x |
| EV / EBITDA | 21.3 x | 18.4 x | 14.4 x |
| EV / FCF | 303 x | 46.8 x | 30.5 x |
| FCF Yield | 0.33% | 2.14% | 3.28% |
| Price to Book | 2.51 x | 2.36 x | 2.2 x |
| Nbr of stocks (in thousands) | 237,898 | - | - |
| Reference price 2 | 81.83 | 81.83 | 81.83 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales 1 | 4,428 | 4,968 | 5,674 |
| EBITDA 1 | 1,026 | 1,159 | 1,425 |
| EBIT 1 | 862.8 | 1,021 | 1,307 |
| Operating Margin | 19.48% | 20.55% | 23.03% |
| Earnings before Tax (EBT) 1 | 323 | 612.5 | 943 |
| Net income 1 | 205.7 | 468 | 749 |
| Net margin | 4.65% | 9.42% | 13.2% |
| EPS 2 | 0.8245 | 2.072 | 3.211 |
| Free Cash Flow 1 | 72 | 455 | 674 |
| FCF margin | 1.63% | 9.16% | 11.88% |
| FCF Conversion (EBITDA) | 7.02% | 39.26% | 47.28% |
| FCF Conversion (Net income) | 35% | 97.21% | 89.99% |
| Dividend per Share 2 | 0.0326 | 0.2758 | 0.4849 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt 1 | 2,352 | 1,807 | 1,105 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | 2.293 x | 1.559 x | 0.7753 x |
| Free Cash Flow 1 | 72 | 455 | 674 |
| ROE (net income / shareholders' equity) | 6.82% | 8.55% | 10.6% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | 32.60 | 34.60 | 37.20 |
| Cash Flow per Share 2 | 32.60 | 18.70 | 4.240 |
| Capex 1 | 246 | 167 | 189 |
| Capex / Sales | 5.55% | 3.35% | 3.33% |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
81.83
USD
Average target price
85.62
USD
Spread / Average Target
+4.63%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 19.47B | |
| +16.21% | 20.87B | |
| +19.29% | 13.16B | |
| -19.32% | 8.65B | |
| +24.34% | 8.02B | |
| +9.98% | 5.95B | |
| -10.60% | 3.97B | |
| -0.61% | 3.85B | |
| -19.10% | 3.73B | |
| -3.77% | 3.62B |
- Stock Market
- Equities
- GALD Stock
- Financials Galderma Group AG
